Clinical Trials Logo

Clinical Trial Summary

This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.


Clinical Trial Description

OBJECTIVES:

I. Identify new molecular categories of Wilms tumor (WT) based on the gene expression profiles of samples from patients with this disease.

II. Develop a classifying system (classifier) that will predict a defined number of clinically relevant categories based on expression of an established set of genes.

III. Confirm and test the classifier with further analysis of the genes by several different methodologies, using additional patient samples that are outside of the case/cohort but which possess the clinically or scientifically relevant parameter.

IV. Validate the use of the classifier to predict defined groups within a second set of samples (for which investigators are blinded to the clinical and biological data) by subsequent comparison with true incidence of pertinent markers.

OUTLINE:

Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00897637
Study type Observational
Source Children's Oncology Group
Contact
Status Completed
Phase N/A
Start date February 2004

See also
  Status Clinical Trial Phase
Completed NCT01118078 - Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor N/A
Completed NCT01305200 - Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Phase 3
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT01614808 - Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor N/A
Completed NCT01502410 - Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Phase 2
Completed NCT00831844 - Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Phase 2
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Completed NCT01586104 - Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases N/A
Completed NCT00309907 - Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Phase 2
Completed NCT00331643 - Ixabepilone in Treating Young Patients With Refractory Solid Tumors Phase 2
Completed NCT00012181 - Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Phase 1